Contact Point for Allegations
Based on the purpose of the “Guidelines for Responding to Misconduct in Research” (the decision made by the Minister of Education, Culture, Sports, Science and Technology on August 26, 2014), Mediplus Pharma, Inc. has established the following contact point for receiving allegations about misconduct in research and development activities.
Contact Point for Receiving Allegations
“Contact Point for Allegations about Misconduct in Research Activities” Corporate Planning Office, Mediplus Pharma, Inc.,
5th Floor, Sreed EBISU, 1-20-4, Ebisu, Shibuya-ku, Tokyo 150-0013 Japan
Method of Filing for Allegations
- Name, affiliation, and contact information of the complainant;
- Name of the researcher or research group suspected of specific research misconduct;
- The nature of the misconduct; and,
- The rational reason for considering it as misconduct.